Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

The price of GLP-1 drugs has attracted the scrutiny of lawmakers, and Novo Nordisk's chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing next week to defend the ...

Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

Half a century of advancements in biomedical science paved the way for today’s powerful weight-loss drugs like Ozempic — so ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

WITH all the buzz around the so-called ‘miracle’ weight-loss jabs Ozempic, you could easily mistake it for a cure for all. Although created to help manage type 2 diabetes the ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

If the drug succeeds, it could offer robust competition to major pharmaceutical companies such as Novo Nordisk and Eli Lilly ... Their VK2735 drug is a GLP-1 dual agonist being developed for patients ...

Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.

This post was written by Melanie Riehl Pharmaceutical giant Novo Nordisk (NVO) stock falls on Friday after receiving ... how the company is looking to bring down the cost of its GLP-1 weight-loss ...

Texas-based Chen wins Albert Lasker Award for discovery of enzyme cGAS, holding out 'promise for fighting infectious diseases ...